- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03294473
Centralized Reminder Recall - Flu RCT2
Centralized IIS-Based Reminder Recall to Increase Influenza Vaccination Rates in New York State - Second Trial in New York State
This study is related to a previous study, Clinicaltrials.gov ID: NCT02924467. There are some modifications in relation to the intervention arms as well as the use of a different cohort, thereby justifying the second submission to Clinicaltrials.gov. This trial is taking place in New York State, through partnership with the New York State Health Department (excluding New York City), and Colorado. Each state will have it's own Clinicaltrial.gov submission -- this was decided as some of the intervention components are different enough that separate registrations were warranted.
Despite U.S. guidelines for influenza vaccination of all children starting at 6 months, only about half of children are vaccinated annually leading to substantial influenza disease in children and spread of disease to adults. A major barrier is that families are not reminded about the need for their children to receive influenza vaccination. The investigators will evaluate the impact of patient reminder/recall (R/R) performed by state immunization information systems to improve influenza vaccination rates by using 4 clinical trials (2 per state) in two different states. The investigators will assess effectiveness and cost-effectiveness of 1) autodialer R/R 2) text messages R/R 3) mailed postcard R/R as compared to 4) standard of care control (no R/R).
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Annual epidemics of influenza A and B cause substantial morbidity and mortality in the US with high rates of hospitalizations, emergency department visits, outpatient visits, and medical costs. Epidemics cause up to 40,000 deaths/year (mostly elderly) and extensive morbidity among children who play a key role in instigating and expanding epidemics. In addition, concerns about pandemic influenza heighten the importance of new mechanisms to rapidly inform the population about influenza and direct efforts for rapid vaccine delivery.
Since 2010, the Advisory Committee on Immunization Practices (ACIP) has recommended influenza vaccination for all children >6 months of age. However, vaccination rates remain very low. For the 2012-2013 season, only 56% of children 2-17years were vaccinated. Modeling studies suggest that as many as 19 million cases of influenza could be prevented if child vaccination rates were raised to 70% nationally.
The most effective strategy recommended by CDC and the Task Force on Community Preventive Services for improving childhood influenza vaccination rates is reminder/recall (R/R), sent by phone or mail, notifying parents of the need to vaccinate their child. We and others have shown that R/R can improve influenza vaccination rates by up to 20%. However, <16% of practices use R/R; barriers are practice costs, insufficient staff time and expertise, and lack of predictability regarding receipt of vaccine supplies.
Statewide immunization information systems (IISs) now exist in all states to track childhood vaccinations, but they have not been used for influenza vaccine R/R because of lack of evidence for their effectiveness and a lack of a template for IIS-based R/R. The investigators have united two leading immunization research groups (Denver, CO and Rochester (lead by personnel at UCLA), NY) to assess the impact of centralized IIS-based influenza vaccine R/R and to evaluate the effect of three types of R/R (autodialer, text message and mail R/R) over usual care. The investigators will also develop tools to aid other states in creating efficient IIS R/R systems for seasonal and possible pandemic influenza outbreaks.
For this second R/R trial in New York State, the intent is to evaluate the impact of reminder recalls, in the form of 1) autodialers 2) text messages and 3) postcards versus the standard of care control group, specifically in relation to raising influenza vaccination rates among children 6m-17 years of age.
The proposed design of this 4-arm RCT:
- standard of care control
- autodialer R/R -- with brief educational messages, practice name and practice phone number
- text message R/R-- with brief educational messages, practice name and practice phone number
- mailed (postcards) R/R-- with brief educational messages, practice name and practice phone number
Hypothesis 1: All IIS-C R/R modalities will be more effective than usual care
Hypothesis 2: Text messaging will be more cost-effective than other modalities
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
California
-
Los Angeles, California, Stati Uniti, 90095
- University of California, Los Angeles
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- a record in the New York State Immunization Information System
- in need of at least one influenza vaccination at the time of the beginning of the study
- affiliated with a participating practice (145 randomly selected)
Exclusion Criteria:
- no record within the New York State Immunization Information System
- up to date on their influenza vaccination
- not affiliated with an eligible practice
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Ricerca sui servizi sanitari
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Autodial R/R
R/R Autodialers:Participants in this group will receive up to 3 influenza vaccination reminders via telephone call - with a brief educational message + practice name + practice phone number
|
Investigators will send out flu vaccine reminder recall notices via autodialer message to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
|
|
Sperimentale: Text Message R/R
R/R Texting: Participants in this group will receive up to 3 influenza vaccination reminders via text message - with a brief educational message + practice name + practice phone number
|
Investigators will send out flu vaccine reminder recall notices via text message to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
|
|
Sperimentale: Postcard R/R
R/R Mailed Postcard:Participants in this group will receive up to 3 influenza vaccination reminders via postcard - with a brief educational message + practice name + practice phone number
|
Investigators will send out flu vaccine reminder recall notices via mailed postcards to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
|
|
Nessun intervento: Standard of Care Control
Participants in this group will not receive any influenza vaccination reminders
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
The primary outcome is receipt of influenza vaccine comparing effectiveness of standard of care control to autodialer, text message and postcard R/R
Lasso di tempo: 6 months
|
Based on our prior studies, we plan to send up to 3 autodialer, text messages or postcards (based on randomization) reminders, roughly every 5-6 weeks.
This will begin in October 2017 and end in December 2017.
Outcomes are assessed at 6 months using IIS data.
|
6 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Cost of the R/R intervention
Lasso di tempo: 6 months
|
A cost-effectiveness analysis will be conducted to determine which modality of R/R (autodialer, text message or mailed postcard) is the most cost-effective in relation to improving influenza vaccination rates.
The cost analysis will also compare autodialer to text, autodialer to postcard, and texting to postcards.
|
6 months
|
Collaboratori e investigatori
Collaboratori
Investigatori
- Investigatore principale: Peter Szilagyi, MD, MPH, University of California, Los Angeles
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 17-001153 (Altro identificatore: University of California, Los Angeles, IRB)
- 1R01AI114903 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Infezioni da virus a RNA
-
University of California, Los AngelesNational Institute on Aging (NIA)Iscrizione su invitoInfezione da virus, RNAStati Uniti
-
National Institute of Allergy and Infectious Diseases...Iscrizione su invitoInfezioni | Infezioni delle vie respiratorie | Infezioni da Orthomyxoviridae | Infezione influenzale | Malattie virali | Infezioni da virus respiratorio | Virus a RNAStati Uniti
-
DR. MALA KHANBangladesh Reference Institute of Chemical Measurements (BRICM)CompletatoEfficacia, Sé | Effetto della droga | Infezione da virus, RNABangladesh
-
Simcere Pharmaceutical Co., LtdReclutamentoInfezione da virus respiratorio sincizialeCina
-
Tam Anh Research InstituteReclutamentoInfezioni da virus respiratorio sinciziale | Infezione da virus respiratorio sincizialeVietnam
-
Ab&B Bio-tech Co., Ltd.JSYither Biotech Co., LtdReclutamentoInfezioni da virus respiratorio sincizialeCina
-
GlaxoSmithKlineReclutamento
-
ShionogiReclutamentoInfezioni da virus respiratorio sincizialeStati Uniti, Bulgaria, Sud Africa, Polonia, Giappone
-
CepheidCompletato
-
CepheidCompletato
Prove cliniche su R/R - Autodialers
-
Klinikum NürnbergSconosciutoSindrome del seno malatoGermania
-
University of California, Los AngelesNational Institute of Allergy and Infectious Diseases (NIAID)CompletatoInfezioni delle vie respiratorie | Influenza | VacciniStati Uniti
-
Shenzhen Salubris Pharmaceuticals Co., Ltd.Non ancora reclutamentoIpertensione primariaCina
-
Sun Yat-sen UniversityNon ancora reclutamentoLinfoma diffuso a grandi cellule B (DLBCL)Cina
-
Daping Hospital and the Research Institute of Surgery...Non ancora reclutamento
-
LifeScanCompletato
-
Sun Yat-sen UniversityNon ancora reclutamentoLinfoma diffuso a grandi cellule B (DLBCL) | CD5 positivoCina
-
Johns Hopkins UniversityNational Institute of Allergy and Infectious Diseases (NIAID)Reclutamento
-
Taiyuan LiCompletatoCancro rettale | Chirurgia robotica | Chirurgia di estrazione del campione di orifizio naturaleCina
-
Vanderbilt University Medical CenterNon ancora reclutamentoMalattia critica | Delirio in terapia intensivaStati Uniti